Core Laboratories (CLB)
NYSE Market Closed
Core Laboratories Inc. is an oilfield services company focused on helping exploration and production companies understand reservoirs and improve hydrocarbon recovery. Its work is centred on the science of rocks, fluids, pressure behaviour, and well performance, giving operators technical data they can use to make drilling, completion, and production decisions.
The company reports through two main businesses: Reservoir Description and Production Enhancement. Reservoir Description provides laboratory analysis, field services, and interpretation of core samples, reservoir fluids, and related geological data. These services help customers assess reservoir quality, estimate reserves, model production potential, and determine how crude oil and natural gas can be recovered and processed more efficiently. This segment is typically the company’s largest source of revenue.
Production Enhancement supplies technologies and services used to increase output from existing and newly completed wells. Its offerings include diagnostic tools, completion products, and systems that support perforating, stimulation, and reservoir monitoring. Core Laboratories also manufactures specialised equipment used in its laboratory and field-service activities, giving it a proprietary product base alongside its consulting and analytical work.
The company serves oil and gas producers around the world and is closely tied to upstream spending, reservoir development activity, and the industry’s focus on extracting more value from existing assets. Its competitive position rests on patented technologies, long-standing customer relationships, and technical expertise in reservoir evaluation rather than on large-scale drilling or commodity production.
Last updated
- Market Cap
- 615.85M
- P/E
- 21.4
- P/FCF
- 33.41
- P/S
- 1.17
- Enterprise Value
- 707.49M
- Sector
- Energy
- Industry
- Oil and Gas Field Services, Not Elsewhere Classified
- Address
- 6316 WINDFERN ROAD, HOUSTON, TX, 77040
Christina Lake Cannabis Announces Filing of Q1 Financial Statements
Christina Lake Cannabis Announces Filing of Audited Financial Statements
Christina Lake Cannabis Provides Bi-Weekly Update on Status of MCTO
Christina Lake Cannabis Provides Bi-Weekly Update on Status of MCTO
Core Laboratories (CLB) Up 6.2% Since Last Earnings Report: Can It Continue?
Christina Lake Cannabis Provides Bi-Weekly Update on Status of MCTO
Core Laboratories (CLB) Q1 Earnings and Sales Beat Estimates
Kinder Morgan (KMI) Beats on Q1 Earnings, Hikes Dividend
Sunoco (SUN) Proceeds With Strategic Portfolio Optimization
What Makes Core Laboratories (CLB) a New Strong Buy Stock
Christina Lake Cannabis Provides Bi-Weekly Update on Status of MCTO
Earnings Preview: Core Laboratories (CLB) Q1 Earnings Expected to Decline
Christina Lake Cannabis Announces Delay in Filing its 2023 Annual Financial Statements
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why Core Laboratories (CLB) is a Top Value Stock for the Long-Term
Christina Lake Cannabis Provides Operations Update
Core Laboratories (CLB) Down 0.4% Since Last Earnings Report: Can It Rebound?
Christina Lake Closes First Tranche of Non-Brokered Private Placement of Secured Convertible Notes
Christina Lake Announces Results of AGM
Here's What Key Metrics Tell Us About Core Laboratories (CLB) Q4 Earnings
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 615.85M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 707.49M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 21.4
- P/B
P/B ratio compares a company's share price to its book value per share.
- 2.29
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 1.17
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 10.31
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 1.35
- EPS
- 0.62
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0.3%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 33.41
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 17.94
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 18.44M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 10.7%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 4.9%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.43
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.05
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.5
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.22
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 540.12K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 13.36
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 121.8M | 138.26M | 134.52M | 130.16M | 123.59M |
| Gross profit | 19.72M | 28.74M | 29.62M | 26.46M | 24.12M |
| Operating income | 1.89M | 15.83M | 20.93M | 15.29M | 4.42M |
| EBITDA | 5.65M | 19.5M | 24.52M | 18.96M | 8.13M |
| Net income | -789K | 4.41M | 14.52M | 10.64M | -154K |
| Basic EPS | -0.02 | 0.1 | 0.31 | 0.23 | — |
| Diluted EPS | -0.02 | 0.1 | 0.31 | 0.22 | — |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 587.73M | 584.01M | 591.36M | 602.11M | 591.52M |
| Total liabilities | 312.58M | 311.8M | 313.97M | 334.81M | 332.16M |
| Total equity | 275.14M | 272.21M | 277.39M | 267.3M | 259.36M |
| Cash & equivalents | 22.82M | 22.7M | 25.63M | 31.19M | 22.11M |
| Current assets | 214.37M | 214.67M | 226.91M | 237.68M | 228.77M |
| Current liabilities | 104.73M | 106.02M | 95.74M | 104.77M | 103.73M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 3.97M | 7.95M | 8.5M | 13.92M | 6.66M |
| Investing cash flow | -3.39M | -3.75M | 2.39M | -1.64M | 772K |
| Financing cash flow | -457K | -7.12M | -16.45M | -3.2M | -4.48M |
| Change in cash | 117K | -2.93M | -5.56M | 9.08M | 2.95M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | SCHEDULE 13G/A — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | SD — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 8-K — Core Laboratories Inc. /DE/ | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 10-Q — Core Laboratories Inc. /DE/ | View Filing | |
| form 4 | Form 4 — Tattoli Mark Damian | View Filing | |
| form 4 | Form 4 — Tattoli Mark Damian | View Filing | |
| form 4 | Form 4 — Tattoli Mark Damian | View Filing | |
| form 4 | Form 4 — Tattoli Mark Damian | View Filing | |
| form 4 | Form 4 — Tattoli Mark Damian | View Filing | |
| edgar index | 8-K — Core Laboratories Inc. /DE/ | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| form 4 | Form 4 — Carnes Martha Z. | View Filing | |
| form 4 | Form 4 — Carnes Martha Z. | View Filing | |
| form 4 | Form 4 — Carnes Martha Z. | View Filing | |
| form 4 | Form 4 — MARTINOVICH ROBERT F | View Filing | |
| form 4 | Form 4 — MARTINOVICH ROBERT F | View Filing | |
| form 4 | Form 4 — MARTINOVICH ROBERT F | View Filing | |
| form 4 | Form 4 — Temeng Kwaku | View Filing | |
| form 4 | Form 4 — Temeng Kwaku | View Filing | |
| form 4 | Form 4 — Temeng Kwaku | View Filing | |
| form 4 | Form 4 — Klingensmith Harvey Robert | View Filing | |
| form 4 | Form 4 — Klingensmith Harvey Robert | View Filing | |
| form 4 | Form 4 — Klingensmith Harvey Robert | View Filing | |
| form 4 | Form 4 — ANASTASIO CURT | View Filing | |
| form 4 | Form 4 — ANASTASIO CURT | View Filing | |
| form 4 | Form 4 — ANASTASIO CURT | View Filing | |
| form 4 | Form 4 — Murray Katherine | View Filing | |
| form 4 | Form 4 — Murray Katherine | View Filing | |
| form 4 | Form 4 — Murray Katherine | View Filing | |
| edgar index | SCHEDULE 13G/A — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 10-K — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 8-K — Core Laboratories Inc. /DE/ | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K/A — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 8-K — Core Laboratories Inc. /DE/ | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | NT 10-K — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | SCHEDULE 13G/A — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | SCHEDULE 13G/A — Core Laboratories Inc. /DE/ | View Filing | |
| form 4 | Form 4 — Teo Sow Hang | View Filing | |
| form 4 | Form 4 — Bruno Lawrence | View Filing | |
| form 4 | Form 4 — Hill Christopher Scott | View Filing | |
| form 4 | Form 4 — Hill Christopher Scott | View Filing | |
| form 4 | Form 4 — Gresham Gwendolyn | View Filing | |
| form 4 | Form 4 — Tattoli Mark Damian | View Filing | |
| edgar index | 8-K — Core Laboratories Inc. /DE/ | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| edgar index | 4 — Core Laboratories Inc. /DE/ | View Filing | |
| form 4 | Form 4 — Bruno Lawrence | View Filing | |
| form 4 | Form 4 — Bruno Lawrence | View Filing | |
| form 4 | Form 4 — Bruno Lawrence | View Filing | |
| form 4 | Form 4 — Hill Christopher Scott | View Filing | |
| form 4 | Form 4 — Hill Christopher Scott | View Filing | |
| form 4 | Form 4 — Hill Christopher Scott | View Filing | |
| form 4 | Form 4 — Gresham Gwendolyn | View Filing | |
| form 4 | Form 4 — Gresham Gwendolyn | View Filing |